Skip to main content

Find a clinical trial

Find a clinical trial

Trial status
Trial Phase
Trial type
244 clinical trials grid list download
  • Title Organ Phase Statut Major inclusion criteria Contact
  • 1206 - HNCG A randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs) Oral cavity and lips phase 2 Closed metastatic, RECIST 1.1 Yassine Lalami
  • 1301-LG 10-day decitabine versus conventional chemotherapy (?3+7?) followed by allografting in AML patients >= 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group Acute leukemia phase 3 Closed 1st line / >= 60 years old / Eligible for standard intensive chemotherapy/ De novo or secondary AML is allowed Dominique Bron
  • 1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Multiple phase 1 Open any line, RECIST 1.1 Ahmad Hussein Awada
  • 1407 GUCC TIGER A Randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors Testicles phase 3 Open Germ cell tumor Thierry Gil
  • 38RC17.290 Characteristics and Care of Solid Tumor Patients Treated With Immunotherapy Admitted in Intensive Care Unit. Solid tumors Closed Treatment by Immunotherapy <6monthsAdmission in intensive care Anne-Pascale Meert
  • 8951-CL-0301 A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Stomach - Duodenum-esogastric junction phase 3 Open Unresecable or metastatic Amelie Deleporte
  • AB11002 AB11002 A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib to sunitinib in patients with gastrointestinla stromal tumor after progression with imatinib. Stomach - Duodenum-esogastric junction phase 3 Closed c-Kit positive. Progression under imatinib Thierry Gil
  • ADRIATIC A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (D933QC00001 - ADRIATIC) Lung phase 3 Open 4 lines chemotherapy and radiation Bogdan Grigoriu
  • AG013-ODOM-201 A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy Head and Neck phase 2 Closed No prior gene therapy Dirk Van Gestel
  • AL-TNBC-01 - TENACITY A Phase 2, Multicenter, Open-label, Single arm Study of AL101 Monotherapy in Patients with Notch Activated Triple Negative Breast Cancer Breast phase 2 Open Philippe Aftimos
  • Allo-Shrink An open-label, Phase I study to assess the safety of multiple doses of CYAD-101, administered after standard FOLFOX chemotherapy in patients with unresectable metastatic colorectal cancer Colon phase 1 Open Unresacable metastasis. RECIST v1.1. Can receive FOLFOX Alain Hendlisz
  • AMC303-01 A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Multiple phase 1/1b Closed any line, RECIST 1.1 Philippe Aftimos
  • AMG420 -20160370 A Phase 1b/2 Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma phase 1/2 Closed Nathalie Meuleman
  • AMG510 A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation Multiple phase 1/2 Closed Locally-advanced or metastatic malignancy with : KRAS p.G12Cmutation Nuria Kotecki